White House pulls Heidi Overton’s FDA nomination a day before committee vote

The withdrawal came the night before a Senate committee vote. Sen. Bill Cassidy disputes the White House account that she lacked the votes.

0
SOURCENationofChange
US Food and Drug Administration Office 20180930.jpg
A Food and Drug Administration office Photo: CaptJayRuffins / Wikimedia Commons (CC BY-SA 4.0)

The White House has withdrawn Dr. Heidi Overton's nomination to lead the Food and Drug Administration, a day before the Senate health committee was set to vote on it. Overton, a physician who grew up in Gallup, New Mexico, had faced questions from senators of both parties.

The White House said Tuesday it pulled the nomination amid growing indications she did not have the votes to win Senate confirmation, the Associated Press reported. CBS News, relying on an administration official and others with knowledge of the decision, reported that the committee had been scheduled to vote on Wednesday.

The arithmetic was tight. According to the AP, she needed all 12 of the committee's Republicans, since Democrats hold 11 seats on the Senate Health, Education, Labor and Pensions (HELP) panel. Without the committee's backing, the AP reported, she faced little chance of a full Senate vote. The Hill noted that GOP leaders could have tried to bring her nomination directly to the floor, but that would likely have met significant obstacles.

Committee chairman Sen. Bill Cassidy, a Louisiana Republican and a physician, disputed the White House's account late Tuesday. He said the problem was not that Overton lacked the votes, and that the White House had "abandoned a viable confirmation path," CBS News reported.

In a statement, Cassidy said "pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues," but the administration withdrew Overton instead. "I believe she would have had the votes to pass out of committee and pass the full Senate," he said. Two sources told CBS News that whip efforts to line up Republican votes were still underway when the White House shared its decision.

Cassidy had been a source of doubt earlier. The AP reported that he called Overton's support for President Donald Trump's plan to split combined vaccines such as the measles, mumps and rubella shot "almost disqualifying," and that he pressed her at a September hearing about her independence from Trump and Health Secretary Robert F. Kennedy Jr. The Hill reported that Overton declined at that hearing to say whether she would stand up to the president or Kennedy. Drug Topics reported that she did tell the panel the measles vaccine is safe and effective.

Abortion policy was a second point of friction. According to The Hill, Overton is openly anti-abortion. Drug Topics reported that she testified the drug is safe and effective as currently labeled, while The Hill reported she would not say directly whether she personally believes mifepristone is safe. Drug Topics added that Republicans were troubled by her noncommittal answers on the FDA's continuing safety review of it. Sen. Lisa Murkowski, an Alaska Republican, questioned her about the drug, according to Searchlight New Mexico.

Vaping also played a role. The AP reported that Sen. Susan Collins of Maine raised concerns about Overton's approach to flavored e-cigarettes. The AP noted that the FDA recently authorized its first fruit-flavored e-cigarettes for adult smokers. CBS News reported that some lawmakers and administration allies were skeptical partly because of her execution of Trump's pro-vape policies. The AP added that prominent voices in the Make America Healthy Again movement opposed her too.

In New Mexico, the withdrawal was welcomed by at least one of her fellow graduates. Overton graduated from the University of New Mexico School of Medicine in 2015, and Searchlight New Mexico reported that more than 50 alumni had signed a letter objecting to her nomination. The letter argued that the agency's leader should have a policy record that aligns with "established clinical consensus and sound regulatory science," in the letter's words.

Dr. Mike Winer, an addiction medicine and family physician from the school's class of 2018, said the decision came as a relief. In a message to The New Mexican, he said the country needs a commissioner whose decisions are "grounded in science," among other qualities.

CBS News reported that the agency has had no Senate-confirmed head since Dr. Marty Makary's forced exit in May. It is now led on an acting basis by Kyle Diamantas, according to the AP. A source told CBS News earlier Tuesday that officials had already begun speaking with other possible picks, some of whom could serve as acting chief and skip Senate confirmation.

Time is short. CBS News reported that confirming any permanent commissioner would have to happen in the narrow window before Democrats take over the Senate in January. Cassidy, who lost his Republican primary in May and has only weeks left in his term, said "with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats." The AP reported that no timetable for a new nominee was immediately known.

Get NationofChange in your inbox

Independent reporting every weekday. No paywall, no advertisers, no corporate owner. Free, and you can unsubscribe whenever you like.

Subscribe free

FALL FUNDRAISER

If you liked this article, please donate $5 to keep NationofChange online through November.

[give_form id="735829"]

COMMENTS